Hydroxysteroid Dehydrogenases: Enzymes of the oxidoreductase class that catalyze the dehydrogenation of hydroxysteroids. (From Enzyme Nomenclature, 1992) EC 1.1.-.11-beta-Hydroxysteroid Dehydrogenase Type 2: An high-affinity, NAD-dependent 11-beta-hydroxysteroid dehydrogenase that acts unidirectionally to catalyze the dehydrogenation of CORTISOL to CORTISONE. It is found predominantly in mineralocorticoid target tissues such as the KIDNEY; COLON; SWEAT GLANDS; and the PLACENTA. Absence of the enzyme leads to a fatal form of childhood hypertension termed, APPARENT MINERALOCORTICOID EXCESS SYNDROME.3-Hydroxysteroid Dehydrogenases: Catalyze the oxidation of 3-hydroxysteroids to 3-ketosteroids.11-beta-Hydroxysteroid Dehydrogenase Type 1: A low-affinity 11 beta-hydroxysteroid dehydrogenase found in a variety of tissues, most notably in LIVER; LUNG; ADIPOSE TISSUE; vascular tissue; OVARY; and the CENTRAL NERVOUS SYSTEM. The enzyme acts reversibly and can use either NAD or NADP as cofactors.17-Hydroxysteroid Dehydrogenases: A class of enzymes that catalyzes the oxidation of 17-hydroxysteroids to 17-ketosteroids. EC 1.1.-.11-beta-Hydroxysteroid Dehydrogenases: Hydroxysteroid dehydrogenases that catalyzes the reversible conversion of CORTISOL to the inactive metabolite CORTISONE. Enzymes in this class can utilize either NAD or NADP as cofactors.20-Hydroxysteroid Dehydrogenases: A group of enzymes that catalyze the reversible reduction-oxidation reaction of 20-hydroxysteroids, such as from a 20-ketosteroid to a 20-alpha-hydroxysteroid (EC 1.1.1.149) or to a 20-beta-hydroxysteroid (EC 1.1.1.53).Steroid 17-alpha-Hydroxylase: A microsomal cytochrome P450 enzyme that catalyzes the 17-alpha-hydroxylation of progesterone or pregnenolone and subsequent cleavage of the residual two carbons at C17 in the presence of molecular oxygen and NADPH-FERRIHEMOPROTEIN REDUCTASE. This enzyme, encoded by CYP17 gene, generates precursors for glucocorticoid, androgen, and estrogen synthesis. Defects in CYP17 gene cause congenital adrenal hyperplasia (ADRENAL HYPERPLASIA, CONGENITAL) and abnormal sexual differentiation.3-alpha-Hydroxysteroid Dehydrogenase (B-Specific): A 3-hydroxysteroid dehydrogenase which catalyzes the reversible reduction of the active androgen, DIHYDROTESTOSTERONE to 5 ALPHA-ANDROSTANE-3 ALPHA,17 BETA-DIOL. It also has activity towards other 3-alpha-hydroxysteroids and on 9-, 11- and 15- hydroxyprostaglandins. The enzyme is B-specific in reference to the orientation of reduced NAD or NADPH.Hydrocortisone: The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions.Estradiol Dehydrogenases: Enzymes that catalyze the oxidation of estradiol at the 17-hydroxyl group in the presence of NAD+ or NADP+ to yield estrone and NADH or NADPH. The 17-hydroxyl group can be in the alpha- or beta-configuration. EC 1.1.1.62Sulfotransferases: Enzymes which transfer sulfate groups to various acceptor molecules. They are involved in posttranslational sulfation of proteins and sulfate conjugation of exogenous chemicals and bile acids. EC 2.8.2.Cortisone: A naturally occurring glucocorticoid. It has been used in replacement therapy for adrenal insufficiency and as an anti-inflammatory agent. Cortisone itself is inactive. It is converted in the liver to the active metabolite HYDROCORTISONE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p726)Alcohol Oxidoreductases: A subclass of enzymes which includes all dehydrogenases acting on primary and secondary alcohols as well as hemiacetals. They are further classified according to the acceptor which can be NAD+ or NADP+ (subclass 1.1.1), cytochrome (1.1.2), oxygen (1.1.3), quinone (1.1.5), or another acceptor (1.1.99).Steroids: A group of polycyclic compounds closely related biochemically to TERPENES. They include cholesterol, numerous hormones, precursors of certain vitamins, bile acids, alcohols (STEROLS), and certain natural drugs and poisons. Steroids have a common nucleus, a fused, reduced 17-carbon atom ring system, cyclopentanoperhydrophenanthrene. Most steroids also have two methyl groups and an aliphatic side-chain attached to the nucleus. (From Hawley's Condensed Chemical Dictionary, 11th ed)NAD: A coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). (Dorland, 27th ed)Kinetics: The rate dynamics in chemical or physical systems.L-Lactate Dehydrogenase: A tetrameric enzyme that, along with the coenzyme NAD+, catalyzes the interconversion of LACTATE and PYRUVATE. In vertebrates, genes for three different subunits (LDH-A, LDH-B and LDH-C) exist.Testosterone: A potent androgenic steroid and major product secreted by the LEYDIG CELLS of the TESTIS. Its production is stimulated by LUTEINIZING HORMONE from the PITUITARY GLAND. In turn, testosterone exerts feedback control of the pituitary LH and FSH secretion. Depending on the tissues, testosterone can be further converted to DIHYDROTESTOSTERONE or ESTRADIOL.Androsterone: A metabolite of TESTOSTERONE or ANDROSTENEDIONE with a 3-alpha-hydroxyl group and without the double bond. The 3-beta hydroxyl isomer is epiandrosterone.Liver: A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances.Alcohol Dehydrogenase: A zinc-containing enzyme which oxidizes primary and secondary alcohols or hemiacetals in the presence of NAD. In alcoholic fermentation, it catalyzes the final step of reducing an aldehyde to an alcohol in the presence of NADH and hydrogen.Glyceraldehyde-3-Phosphate Dehydrogenases: Enzymes that catalyze the dehydrogenation of GLYCERALDEHYDE 3-PHOSPHATE. Several types of glyceraldehyde-3-phosphate-dehydrogenase exist including phosphorylating and non-phosphorylating varieties and ones that transfer hydrogen to NADP and ones that transfer hydrogen to NAD.20-alpha-Hydroxysteroid Dehydrogenase: An enzymes that catalyzes the reversible reduction-oxidation reaction of 20-alpha-hydroxysteroids, such as from PROGESTERONE to 20-ALPHA-DIHYDROPROGESTERONE.Aldehyde Dehydrogenase: An enzyme that oxidizes an aldehyde in the presence of NAD+ and water to an acid and NADH. This enzyme was formerly classified as EC 1.1.1.70.Glutamate Dehydrogenase: An enzyme that catalyzes the conversion of L-glutamate and water to 2-oxoglutarate and NH3 in the presence of NAD+. (From Enzyme Nomenclature, 1992) EC 1.4.1.2.Glucosephosphate DehydrogenaseMalate Dehydrogenase: An enzyme that catalyzes the conversion of (S)-malate and NAD+ to oxaloacetate and NADH. EC 1.1.1.37.Isocitrate Dehydrogenase: An enzyme of the oxidoreductase class that catalyzes the conversion of isocitrate and NAD+ to yield 2-ketoglutarate, carbon dioxide, and NADH. It occurs in cell mitochondria. The enzyme requires Mg2+, Mn2+; it is activated by ADP, citrate, and Ca2+, and inhibited by NADH, NADPH, and ATP. The reaction is the key rate-limiting step of the citric acid (tricarboxylic) cycle. (From Dorland, 27th ed) (The NADP+ enzyme is EC 1.1.1.42.) EC 1.1.1.41.Phosphoadenosine Phosphosulfate: 3'-Phosphoadenosine-5'-phosphosulfate. Key intermediate in the formation by living cells of sulfate esters of phenols, alcohols, steroids, sulfated polysaccharides, and simple esters, such as choline sulfate. It is formed from sulfate ion and ATP in a two-step process. This compound also is an important step in the process of sulfur fixation in plants and microorganisms.Arylsulfotransferase: A sulfotransferase that catalyzes the sulfation of a phenol in the presence of 3'-phosphoadenylylsulfate as sulfate donor to yield an aryl sulfate and adenosine 3',5'-bisphosphate. A number of aromatic compounds can act as acceptors; however, organic hydroxylamines are not substrates. Sulfate conjugation by this enzyme is a major pathway for the biotransformation of phenolic and catechol drugs as well as neurotransmitters. EC 2.8.2.1.Ketosteroids: Steroid derivatives formed by oxidation of a methyl group on the side chain or a methylene group in the ring skeleton to form a ketone.NADP: Nicotinamide adenine dinucleotide phosphate. A coenzyme composed of ribosylnicotinamide 5'-phosphate (NMN) coupled by pyrophosphate linkage to the 5'-phosphate adenosine 2',5'-bisphosphate. It serves as an electron carrier in a number of reactions, being alternately oxidized (NADP+) and reduced (NADPH). (Dorland, 27th ed)Dihydrolipoamide Dehydrogenase: A flavoprotein containing oxidoreductase that catalyzes the reduction of lipoamide by NADH to yield dihydrolipoamide and NAD+. The enzyme is a component of several MULTIENZYME COMPLEXES.Carbohydrate Dehydrogenases: Reversibly catalyze the oxidation of a hydroxyl group of carbohydrates to form a keto sugar, aldehyde or lactone. Any acceptor except molecular oxygen is permitted. Includes EC 1.1.1.; EC 1.1.2.; and 1.1.99.Succinate Dehydrogenase: A flavoprotein containing oxidoreductase that catalyzes the dehydrogenation of SUCCINATE to fumarate. In most eukaryotic organisms this enzyme is a component of mitochondrial electron transport complex II.L-Iditol 2-Dehydrogenase: An alcohol oxidoreductase which catalyzes the oxidation of L-iditol to L-sorbose in the presence of NAD. It also acts on D-glucitol to form D-fructose. It also acts on other closely related sugar alcohols to form the corresponding sugar. EC 1.1.1.14Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.Glycerolphosphate DehydrogenaseMolecular Sequence Data: Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.Substrate Specificity: A characteristic feature of enzyme activity in relation to the kind of substrate on which the enzyme or catalytic molecule reacts.Glucose 1-Dehydrogenase: A glucose dehydrogenase that catalyzes the oxidation of beta-D-glucose to form D-glucono-1,5-lactone, using NAD as well as NADP as a coenzyme.Ketoglutarate Dehydrogenase ComplexAldehyde Oxidoreductases: Oxidoreductases that are specific for ALDEHYDES.
(1/232) Retinoic acid stimulates the expression of 11beta-hydroxysteroid dehydrogenase type 2 in human choriocarcinoma JEG-3 cells.

The syncytiotrophoblasts of the human placenta express high levels of 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2), the enzyme responsible for the inactivation of glucocorticoids. It has been proposed that the placental 11beta-HSD2 serves as a barrier to protect the fetus from high levels of maternal cortisol. To examine the hypothesis that nutritional signals regulate the expression of 11beta-HSD2 in placental syncytiotrophoblasts, we investigated the effects of retinoic acids (RAs), the major metabolites of vitamin A, on the expression of 11beta-HSD2 using human choriocarcinoma JEG-3 cells as a model. This trophoblast-like cell line displays a number of functional similarities to the syncytiotrophoblast. Treatment for 24 h with all-trans RA (1-1000 nM) resulted in a dose-dependent increase in 11beta-HSD2 activity with a maximal effect (increase to 3-fold) at 100 nM. The effect of all-trans RA (100 nM) was also time-dependent in that the effect was detectable at 6 h and reached its maximum by 48 h. Similar increases in 11beta-HSD2 activity were observed when the cells were treated with 9-cis RA. Results from semi-quantitative reverse transcription-polymerase chain reaction demonstrated that there was a corresponding increase in 11beta-HSD2 mRNA after RA treatment. Moreover, treatment with actinomycin D (100 ng/ml) abrogated the increase in 11beta-HSD2 mRNA induced by RA, indicating an effect on transcription. In conclusion, the present study has demonstrated for the first time that RA, at physiological concentrations, induces 11beta-HSD2 gene expression and enzyme activity in JEG-3 cells. If this occurs in vivo, the present finding suggests that high expression of 11beta-HSD2 in the human placenta may be maintained, at least in part, by dietary intake of vitamin A.  (+info)

(2/232) Developmental expression of sodium entry pathways in rat nephron.

During the past several years, sites of expression of ion transport proteins in tubules from adult kidneys have been described and correlated with functional properties. Less information is available concerning sites of expression during tubule morphogenesis, although such expression patterns may be crucial to renal development. In the current studies, patterns of renal axial differentiation were defined by mapping the expression of sodium transport pathways during nephrogenesis in the rat. Combined in situ hybridization and immunohistochemistry were used to localize the Na-Pi cotransporter type 2 (NaPi2), the bumetanide-sensitive Na-K-2Cl cotransporter (NKCC2), the thiazide-sensitive Na-Cl cotransporter (NCC), the Na/Ca exchanger (NaCa), the epithelial sodium channel (rENaC), and 11beta-hydroxysteroid dehydrogenase (11HSD). The onset of expression of these proteins began in post-S-shape stages. NKCC2 was initially expressed at the macula densa region and later extended into the nascent ascending limb of the loop of Henle (TAL), whereas differentiation of the proximal tubular part of the loop of Henle showed a comparatively retarded onset when probed for NaPi2. The NCC was initially found at the distal end of the nascent distal convoluted tubule (DCT) and later extended toward the junction with the TAL. After a period of changing proportions, subsegmentation of the DCT into a proximal part expressing NCC alone and a distal part expressing NCC together with NaCa was evident. Strong coexpression of rENaC and 11HSD was observed in early nascent connecting tubule (CNT) and collecting ducts and later also in the distal portion of the DCT. Ontogeny of the expression of NCC, NaCa, 11HSD, and rENaC in the late distal convolutions indicates a heterogenous origin of the CNT. These data present a detailed analysis of the relations between the anatomic differentiation of the developing renal tubule and the expression of tubular transport proteins.  (+info)

(3/232) Inhibition of 11 beta-hydroxysteroid dehydrogenase obtained from guinea pig kidney by some bioflavonoids and triterpenoids.

AIM: To study the inhibitory effect of some bioflavonoids and triterpenoids on 11 beta-hydroxysteroid dehydrogenase (11 beta-OHSD) from guinea pig kidney. METHOD: The 11 beta-OHSD of kidney cortex microsomes in addition of cortisol was incubated in the presence of NADP, Triton DF-18, and the test compounds at 37 degrees C for 1 h. The enzyme activity was assayed by measuring the rate of conversion of cortisol to cortisone eluted with HPLC gradient analysis. RESULTS: The IC50 (95% confidence limits) values of glycyrrhizic acid, naringenin, fisetin, emodin were 254 (202-320), 336 (270-418), 470 (392-564), and 527 (425-653) mumol.L-1, respectively. The inhibitory effect of oleanolic acid was 2-fold stronger than that of astramembranin I. The mode of action of naringenin was competitive inhibition. CONCLUSION: The test compounds inhibited the 11 beta-OHSD in kidney cortex with different potencies as glycyrrhizic acid did.  (+info)

(4/232) Hypertension in mice lacking 11beta-hydroxysteroid dehydrogenase type 2.

Deficiency of 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) in humans leads to the syndrome of apparent mineralocorticoid excess (SAME), in which cortisol illicitly occupies mineralocorticoid receptors, causing sodium retention, hypokalemia, and hypertension. However, the disorder is usually incompletely corrected by suppression of cortisol, suggesting additional and irreversible changes, perhaps in the kidney. To examine this further, we produced mice with targeted disruption of the 11beta-HSD2 gene. Homozygous mutant mice (11beta-HSD2(-/-)) appear normal at birth, but approximately 50% show motor weakness and die within 48 hours. Both male and female survivors are fertile but exhibit hypokalemia, hypotonic polyuria, and apparent mineralocorticoid activity of corticosterone. Young adult 11beta-HSD2(-/-) mice are markedly hypertensive, with a mean arterial blood pressure of 146 +/- 2 mmHg, compared with 121 +/- 2 mmHg in wild-type controls and 114 +/- 4 mmHg in heterozygotes. The epithelium of the distal tubule of the nephron shows striking hypertrophy and hyperplasia. These histological changes do not readily reverse with mineralocorticoid receptor antagonism in adulthood. Thus, 11beta-HSD2(-/-) mice demonstrate the major features of SAME, providing a unique rodent model to study the molecular mechanisms of kidney resetting leading to hypertension.  (+info)

(5/232) Glucocorticoids and insulin resistance: old hormones, new targets.

Insulin resistance has been proposed as a mediator of the association between risk factors for cardiovascular disease in the population. The clinical syndrome of glucocorticoid excess (Cushing's syndrome) is associated with glucose intolerance, obesity and hypertension. By opposing the actions of insulin, glucocorticoids could contribute to insulin resistance and its association with other cardiovascular risk factors. In this review, we describe briefly the known mechanisms of insulin resistance and highlight the potential mechanisms for the effect of glucocorticoids. We then discuss factors which modulate the influence of glucocorticoids on insulin sensitivity; this highlights a novel therapeutic strategy to manipulate glucocorticoid action which may prove to be a useful tool in treating subjects with insulin resistance. Finally, we describe evidence from human studies that glucocorticoids make an important contribution to the pathophysiology of insulin resistance in the population.  (+info)

(6/232) Targeting proteins to the lumen of endoplasmic reticulum using N-terminal domains of 11beta-hydroxysteroid dehydrogenase and the 50-kDa esterase.

Previous studies identified two intrinsic endoplasmic reticulum (ER) proteins, 11beta-hydroxysteroid dehydrogenase, isozyme 1 (11beta-HSD) and the 50-kDa esterase (E3), sharing some amino acid sequence motifs in their N-terminal transmembrane (TM) domains. Both are type II membrane proteins with the C terminus projecting into the lumen of the ER. This finding implied that the N-terminal TM domains of 11beta-HSD and E3 may constitute a lumenal targeting signal (LTS). To investigate this hypothesis we created chimeric fusions using the putative targeting sequences and the reporter gene, Aequorea victoria green fluorescent protein. Transfected COS cells expressing LTS-green fluorescent protein chimeras were examined by fluorescent microscopy and electron microscopic immunogold labeling. The orientation of expressed chimeras was established by immunocytofluorescent staining of selectively permeabilized COS cells. In addition, protease protection assays of membranes in the presence and absence of detergents was used to confirm lumenal or the cytosolic orientation of the constructed chimeras. To investigate the general applicability of the proposed LTS, we fused the N terminus of E3 to the N terminus of the NADH-cytochrome b5 reductase lacking the myristoyl group and N-terminal 30-residue membrane anchor. The orientation of the cytochrome b5 reductase was reversed, from cytosolic to lumenal projection of the active domain. These observations establish that an amino acid sequence consisting of short basic or neutral residues at the N terminus, followed by a specific array of hydrophobic residues terminating with acidic residues, is sufficient for lumenal targeting of single-pass proteins that are structurally and functionally unrelated.  (+info)

(7/232) NAD- and NADP-dependent 11 beta-hydroxysteroid dehydrogenase isoforms in guinea pig kidney with gossypol inhibition.

AIM: To study the mechanism of gossypol-induced hypokalemia. METHODS: The 11 beta-hydroxysteroid dehydrogenase (11 beta-OHSD) protein was prepared from guinea pig kidney. The activity of 11 beta-OHSD with NAD or NADP as the coenzyme was measured by HPLC in both control and gossypol treatment. RESULTS: The Vmax and K(m) were 0.64 mmol.h-1/g protein and 0.07 mumol (cortisol) for NAD-dependent 11 beta-OHSD, 1.75 mmol.h-1/g protein and 0.21 mumol (cortisol) for NADP-dependent 11 beta-OHSD, respectively when 80 micrograms of enzyme protein was used. The inhibitory effects of gossypol on these two 11 beta-OHSD isoforms were different. The IC50 (95% confidence limits) were 50.2 (48.3-52.0) mumol of gossypol for NAD-dependent 11 beta-OHSD and 1143 (1098-1188) mumol of gossypol for NADP-dependent 11 beta-OHSD. The Ki was gossypol 96 mmol.L-1 for the former and 340 mmol.L-1 for the latter. CONCLUSION: The NAD-dependent 11 beta-OHSD is a more critical physiologic mechanism than NADP-dependent 11 beta-OHSD for hypokalemia caused by gossypol.  (+info)

(8/232) Glucocorticoid resistance caused by reduced expression of the glucocorticoid receptor in cells from human vascular lesions.

Mechanisms that control the balance between cell proliferation and death are important in the development of vascular lesions. Rat primary smooth muscle cells were 80% inhibited by low microgram doses of hydrocortisone (HC) and 50% inhibited by nanogram concentrations of transforming growth factor-beta1 (TGF-beta1), although some lines acquired resistance in late passage. However, comparable doses of HC, or TGF-beta1, failed to inhibit most human lesion-derived cell (LDC) lines. In sensitive LDC, HC (10 microg/mL) inhibited proliferation by up to 50%, with obvious apoptosis in some lines, and TGF-beta1 inhibited proliferation by more than 90%. Collagen production, as measured by [3H]proline incorporation or RIA for type III pro-collagen, was either unaffected or increased in the LDCs by HC. These divergent responses between LDC lines were partially explained by the absence of the glucocorticoid receptor (GR) and heat shock protein 90 mRNA in 10 of 12 LDC lines, but the presence of the mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase type II. Western blot analysis confirmed the absence of the GR protein in cells lacking GR mRNA. Immunohistochemistry of human carotid lesions showed high levels of GR in the tunica media, but large areas lacking GR in the fibrous lesion. Considering the absence of the GR in most lines, the effects of HC may be elicited through the mineralocorticoid receptor. Functional resistance to the antiproliferative and antifibrotic effects of HC may contribute to excessive wound repair in atherosclerosis and restenosis.  (+info)

*  11β-Hydroxysteroid dehydrogenase type 1
Pácha J, Lisá V, Miksík I (February 2002). "Effect of cellular differentiation on 11beta-hydroxysteroid dehydrogenase activity ... Wake DJ, Walker BR (February 2006). "Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 in obesity". Endocrine. 29 (1): ... Agarwal AK (November 2003). "Cortisol metabolism and visceral obesity: role of 11beta-hydroxysteroid dehydrogenase type I ... "11beta-Hydroxysteroid dehydrogenase types 1 and 2 are up- and downregulated in cortisol-secreting adrenal adenomas". Journal of ...
*  DHRS7B
Dehydrogenase/reductase (SDR family) member 7B is an enzyme encoded by the DHRS7B gene in humans, found on chromosome 17p11.2. ... DHRS7B is a member of the short chain dehydrogenase/reductase (SDR) superfamily and possesses characteristic features of an SDR ... Dehydrogenase/reductase (SDR family) member 7B". "Genecards: DHRS7B Gene protein-coding GIFtS 47". Tannin GM, Agarwal AK, ... Downstream of DHSRS7B on the negative strand of chromosome 17p11.2 is the gene Transmembrane protein 11 (TMEM11), and on the ...
*  Corticosteroid 11-beta-dehydrogenase isozyme 2
2005). "11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response". Endocr. Rev. 25 (5 ... Persu A (2005). "11beta-Hydroxysteroid deshydrogenase: a multi-faceted enzyme". J. Hypertens. 23 (1): 29-31. doi:10.1097/ ... "Entrez Gene: HSD11B2 hydroxysteroid (11-beta) dehydrogenase 2". Geerling, Joel C.; Arthur D. Loewy (September 2009). " ... 80 (11): 3145-50. doi:10.1210/jc.80.11.3145. PMID 7593417. Wilson RC, Krozowski ZS, Li K, et al. (1995). "A mutation in the ...
*  HSD2 neurons
Geerling, JC; Engeland, WC; Kawata, M; Loewy, AD (Jan 11, 2006). "Aldosterone target neurons in the nucleus tractus solitarius ... Roland, BL; Li, KX; Funder, JW (Oct 1995). "Hybridization histochemical localization of 11 beta-hydroxysteroid dehydrogenase ... and 11-beta-hydroxysteroid dehydrogenase type 2 (HSD2). HSD2 is an enzyme that metabolizes cortisol and other ...
*  11β-Hydroxysteroid dehydrogenase
Seckl JR (January 1997). "11beta-Hydroxysteroid dehydrogenase in the brain: a novel regulator of glucocorticoid action?". Front ... 11beta-hydroxysteroid dehydrogenase type 1- a tissue-specific amplifier of glucocorticoid action". Endocrinology. 142 (4): 1371 ... The systematic name of this enzyme class is 11beta-hydroxysteroid:NADP+ 11-oxidoreductase. Other names in common use include ... the two substrates of this enzyme are 11beta-hydroxysteroid and NADP+, whereas its 3 products are 11-oxosteroid, NADPH, and H+ ...
*  Roxibolone
17 beta-dihydroxy-17-methyl-1, 4-androstadien-3-one and related compounds". Steroids. 43 (3): 271-82. doi:10.1016/0039-128x(84) ... In accordance, 11α- and 11β-hydroxyprogesterone are known to be potent inhibitors of 11β-hydroxysteroid dehydrogenase (11β-HSD ... However, formebolone was found to be a very weak inhibitor of 11β-HSD type 2, although this specific isoenzyme is responsible ... Roxibolone (INN) (developmental code name BR-906), also known as 11β,17β-dihydroxy-17α-methyl-3-oxoandrosta-1,4-diene-2- ...
*  Mineralocorticoid
This enzyme, 11-beta hydroxysteroid dehydrogenase type II (Protein:HSD11B2), catalyzes the deactivation of glucocorticoids to ... 11 ed)., Saunders Elsevier, Philadelphia, pp. 445-504. Bennett PN and Brown MJ (2008) "Adrenal corticosteroids, antagonists, ... 11-dehydro metabolites. Licorice is known to be an inhibitor of this enzyme and chronic consumption can result in a condition ...
*  Chloroprednisone
This may be due to limited activity topically because the skin lacks the necessary activating enzyme 11-Beta hydroxysteroid ... dehydrogenase. Systemically, this agent's activity on Glucocorticoid receptors may not have competed with agents like ...
*  Pseudohyperaldosteronism
Licorice inhibits the 11-beta hydroxysteroid dehydrogenase type II (Protein:HSD11B2) enzyme resulting in inappropriate ...
*  Cortisol
"11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response". Endocrine Reviews. 25 (5 ... 5-beta THF), reactions for which 5-alpha reductase and 5-beta reductase are the rate-limiting factors, respectively. 5-Beta ... "Cortisol release from adipose tissue by 11beta-hydroxysteroid dehydrogenase type 1 in humans". Diabetes. 58 (1): 46-53. doi: ... II beta-hydroxylation". Acta Endocrin. Copenh. 69: I 701-717, II 718-730. LaCelle PL, Morgan ES, Atwater EC (1964). "An ...
*  Hypokalemia
These hormones and medications include insulin, epinephrine, and other beta agonists (e.g. salbutamol or salmeterol), and ... Hypertension and hypokalemia can also be seen with a deficiency of the 11-beta-hydroxysteroid dehydrogenase type 2 enzyme which ...
*  Cortisone reductase deficiency
"Mutations in the genes encoding 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to ... beta}-hydroxysteroid dehydrogenase type 1 activity". Endocrinology. 146 (6): 2539-43. doi:10.1210/en.2005-0117. PMID 15774558. ... "Mutations in the genes encoding 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to ... Tomlinson, J. W.; Stewart, P. M. (2001). "Cortisol metabolism and the role of 11beta-hydroxysteroid dehydrogenase". Best ...
*  List of diseases (0-9)
17 alpha hydroxylase deficiency 17 beta hydroxysteroide dehydrogenase deficiency 17-beta-hydroxysteroid dehydrogenase ... 3 beta hydroxysteroid dehydrogenase deficiency 3 hydroxyisobutyric aciduria 3 methylcrotonic aciduria 3 methylglutaconyl coa ... Diseases Alphabetical list 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z See also Health Exercise Nutrition 11 beta ... hydratase deficiency 3-hydroxy 3-methyl glutaryl-coa lyase deficiency 3-hydroxyacyl-coa dehydrogenase deficiency 3 ...
*  HSD17B11
"17 beta-hydroxysteroid dehydrogenase type XI localizes to human steroidogenic cells". Endocrinology. 144 (5): 2084-91. doi: ... "Entrez Gene: HSD17B11 hydroxysteroid (17-beta) dehydrogenase 11". Li KX, Smith RE, Krozowski ZS (1999). "Cloning and expression ... Estradiol 17-beta-dehydrogenase 11 is an enzyme that in humans is encoded by the HSD17B11 gene. GRCh38: Ensembl release 89: ... Haeseleer F, Palczewski K (2000). "Short-chain dehydrogenases/reductases in retina". Methods in Enzymology. 316: 372-83. doi: ...
*  Carbenoxolone
2004). "11Beta-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics ... 11α-Hydroxyprogesterone Connors BW (2012). "Tales of a Dirty Drug: Carbenoxolone, Gap Junctions, and Seizures". Epilepsy Curr. ... Carbenoxolone may decrease the amount of active glucocortocoid in the brain, because the drug inhibits 11β-HSD, an enzyme which ... Carbenoxolone reversibly inhibits the conversion of cortisol to the inactive metabolite cortisone by blocking 11β- ...
*  CYP7B1
... possible interference with type 1 11beta-hydroxysteroid dehydrogenase-mediated processes". J. Steroid Biochem. Mol. Biol. 104 ( ... "CYP7B generates a selective estrogen receptor beta agonist in human prostate". J. Clin. Endocrinol. Metab. 89 (6): 2928-35. doi ...
*  List of MeSH codes (D08)
3-hydroxysteroid dehydrogenases MeSH D08.811.682.047.436.350.100 --- 3alpha-hydroxysteroid dehydrogenase (B-specific) MeSH ... 4-beta-glucosidase MeSH D08.811.277.450.420.200.600 --- glucan endo-1,3-beta-d-glucosidase MeSH D08.811.277.450.420.375 --- ... 20-hydroxysteroid dehydrogenases MeSH D08.811.682.047.436.400.074 --- 20alpha-hydroxysteroid dehydrogenase MeSH D08.811.682.047 ... 17-hydroxysteroid dehydrogenases MeSH D08.811.682.047.436.375.280 --- estradiol dehydrogenases MeSH D08.811.682.047.436.400 ...
*  Apparent mineralocorticoid excess syndrome
Weizmann Institute of Science > GeneCards > hydroxysteroid (11-beta) dehydrogenase 2 Archived June 2, 2011, at the Wayback ... Liquorice consumption may also cause a temporary form of AME due to its ability to block 11β-hydroxysteroid dehydrogenase type ... It results from mutations in the HSD11B2 gene, which encodes the kidney isozyme of 11β-hydroxysteroid dehydrogenase type 2. In ... Inborn errors of steroid metabolism 11β-Hydroxylase I deficiency Hyperaldosteronism Pseudohyperaldosteronism Glucocorticoid- ...
*  11β-Hydroxyprogesterone
... (11β-OHP), also known as 21-deoxycorticosterone, as well as 11β-hydroxypregn-4-ene-3,20-dione, is a ... Increased levels of 11β-OHP occur in 21-hydroxylase deficiency. Along with its epimer 11α-hydroxyprogesterone (11α-OHP), 11β- ... Souness GW, Latif SA, Laurenzo JL, Morris DJ (1995). "11 alpha- and 11 beta-hydroxyprogesterone, potent inhibitors of 11 beta- ... hydroxysteroid dehydrogenase (isoforms 1 and 2), confer marked mineralocorticoid activity on corticosterone in the ADX rat". ...
*  Formebolone
... beta)-diol-3-one) in humans". J. Int. Med. Res. 4 (2): 96-105. doi:10.1177/030006057600400203. PMID 799985. Cerutti S, Forlani ... 17 beta-dihydroxy-17-methyl-1, 4-androstadien-3-one and related compounds". Steroids. 43 (3): 271-82. doi:10.1016/0039-128x(84) ... Indeed, 11α- and 11β-hydroxyprogesterone (formebolone and roxibolone being 11α- and 11β-hydroxylated (respectively) similarly) ... Souness GW, Latif SA, Laurenzo JL, Morris DJ (1995). "11 alpha- and 11 beta-hydroxyprogesterone, potent inhibitors of 11 beta- ...
*  11α-Hydroxyprogesterone
11α-OHP is a more potent inhibitor of 11β-HSD than enoxolone (glycyrrhetinic acid) or carbenoxolone in vitro (IC50 = 0.9 nM; ... 11 alpha-Hydroxyprogesterone (11 alpha OH-P) was an order of magnitude more potent a competitive inhibitor of the 11 beta HSD-2 ... In 1995, 11α-OHP, along with its epimer 11β-hydroxyprogesterone, was identified as a very potent competitive inhibitor of both ... 11α-OHP is used as a precursor in chemical syntheses of cortisone and hydrocortisone. Steroidal antiandrogen List of steroidal ...
*  H6PD
2003). "Mutations in the genes encoding 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase ... Ikegwuonu FI, Jefcoate CR (1999). "Evidence for the involvement of the fatty acid and peroxisomal beta-oxidation pathways in ... "Entrez Gene: H6PD hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase)". Tan SG, Ashton GC (1976). "An autosomal glucose- ... Beutler E, Morrison M (1968). "Localization and characteristics of hexose 6-phosphate dehydrogenase (glucose dehydrogenase)". J ...
*  17β-Hydroxysteroid dehydrogenase III deficiency
"HSD17B3 hydroxysteroid 17-beta dehydrogenase 3 [Homo sapiens (human)] - Gene - NCBI". www.ncbi.nlm.nih.gov. Retrieved 2017-03- ... "17-beta hydroxysteroid dehydrogenase 3 deficiency". Genetics Home Reference. Retrieved 2017-03-11. "OMIM Entry - # 264300 - 17- ... "Orphanet: 46,XY disorder of sex development due to 17 beta hydroxysteroid dehydrogenase 3 deficiency". www.orpha.net. Retrieved ... "OMIM Entry - * 605573 - 17-BETA HYDROXYSTEROID DEHYDROGENASE III; HSD17B3". omim.org. Retrieved 2017-03-13. Pubchem. " ...
*  17β-Hydroxysteroid dehydrogenase
3(or 17)beta-hydroxysteroid dehydrogenase at the US National Library of Medicine Medical Subject Headings (MeSH) Molecular and ... Mindnich R, Möller G, Adamski J (2004). "The role of 17 beta-hydroxysteroid dehydrogenases". Mol. Cell. Endocrinol. 218 (1-2): ... Schultz RM, Groman EV, Engel LL (June 1977). "3(17)beta-Hydroxysteroid dehydrogenase of Pseudomonas testosteroni. A convenient ... Talalay P, Dobson MM (December 1953). "Purification and properties of a beta-hydroxysteroid dehydrogenase". The Journal of ...
*  Mineralocorticoid receptor
Zennaro MC, Farman N, Bonvalet JP, Lombès M (1997). "Tissue-specific expression of alpha and beta messenger ribonucleic acid ... 11β-HSD2), that converts cortisol to inactive cortisone. It also responds to some progestins. Spironolactone and eplerenone are ... Corticosteroid 11-beta-dehydrogenase isozyme 2 (a.k.a. 11β-hydroxysteroid dehydrogenase 2; ...
On-column ligand exchange for structure-based drug design: a case study with human 11[beta]-hydroxysteroid dehydrogenase type 1...  On-column ligand exchange for structure-based drug design: a case study with human 11[beta]-hydroxysteroid dehydrogenase type 1...
2013-11-15. OSTI Identifier:. 1090101. Resource Type:. Journal Article. Resource Relation:. Journal Name: Acta Crystallogr. F; ... Journal Article: On-column ligand exchange for structure-based drug design: a case study with human 11[beta]-hydroxysteroid ... Title: On-column ligand exchange for structure-based drug design: a case study with human 11[beta]-hydroxysteroid dehydrogenase ...
more infohttps://www.osti.gov/scitech/biblio/1090101-column-ligand-exchange-structure-based-drug-design-case-study-human-beta-hydroxysteroid-dehydrogenase-type
3 beta hydroxysteroid dehydrogenase deficiency (Symptoms, signs, causes, treatments & definition) - Medigest  3 beta hydroxysteroid dehydrogenase deficiency (Symptoms, signs, causes, treatments & definition) - Medigest
Medigest has all you need to know about 3 beta hydroxysteroid dehydrogenase deficiency - Symptoms and Signs, Causes, Treatments ... Looking for information on 3 beta hydroxysteroid dehydrogenase deficiency? ... 3 beta hydroxysteroid dehydrogenase deficiency Below you will find more information about 3 beta hydroxysteroid dehydrogenase ... Discuss 3 beta hydroxysteroid dehydrogenase deficiency in our forums Discuss 3 beta hydroxysteroid dehydrogenase deficiency ...
more infohttps://www.medigest.uk/diseases/3-beta-hydroxysteroid-dehydrogenase-deficiency/
What does 11-beta-hydroxysteroid dehydrogenases stand for?  What does 11-beta-hydroxysteroid dehydrogenases stand for?
Beta' is one option -- get in to view more @ The Web's largest and most authoritative acronyms and abbreviations resource. ... Looking for the definition of 11-beta-hydroxysteroid dehydrogenases? Find out what is the full meaning of 11-beta- ... Hydroxysteroid dehydrogenases that catalyzes the reversible conversion of CORTISOL to the inactive metabolite CORTISONE. ... What does 11-beta-hydroxysteroid dehydrogenases mean? This page is about the various possible meanings of the acronym, ...
more infohttp://www.abbreviations.com/serp.php?st=11-beta-hydroxysteroid%20dehydrogenases&qtype=3
Class-Specific Histone Deacetylase Inhibitors Promote 11-Beta Hydroxysteroid Dehydrogenase Type 2 Expression in JEG-3 Cells  Class-Specific Histone Deacetylase Inhibitors Promote 11-Beta Hydroxysteroid Dehydrogenase Type 2 Expression in JEG-3 Cells
H. Guan, K. Sun, and K. Yang, "The ERK1/2 signaling pathway regulates 11beta-hydroxysteroid dehydrogenase type 2 expression in ... H. Zhu, C. Zou, X. Fan et al., "Upregulation of 11beta-hydroxysteroid dehydrogenase type 2 expression by Hedgehog ligand ... β-hydroxysteroid dehydrogenase-2 in the placenta and fetal brain," PLoS ONE, vol. 7, no. 6, Article ID e39791, 2012. View at ... β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) expression in human trophoblast cells through modulation of 11β-HSD2 messenger ...
more infohttps://www.hindawi.com/journals/ijcb/2017/6169310/
HSD11b2 recombinant protein | 11-Beta-Hydroxysteroid Dehydrogenase Type 2 Recombinant Protein-AAC50356.1  HSD11b2 recombinant protein | 11-Beta-Hydroxysteroid Dehydrogenase Type 2 Recombinant Protein-AAC50356.1
11-Beta-Hydroxysteroid Dehydrogenase Type 2 Recombinant Protein-AAC50356.1 (MBS2031421) product datasheet at MyBioSource, ... Belongs to the short-chain dehydrogenases/reductases (SDR) family.. Protein type: Oxidoreductase; Lipid Metabolism - C21- ... HSD11b2 recombinant protein :: 11-Beta-Hydroxysteroid Dehydrogenase Type 2 Recombinant Protein. Catalog #. MBS2031421 (SPECIAL ... 11 publications with HSD11b2 and Inflammation. Renal Insufficiency Antibodies. >9 publications with HSD11b2 and Renal ...
more infohttps://www.mybiosource.com/hsd11b2-recombinant-protein/11-beta-hydroxysteroid-dehydrogenase-type-2/2031421
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase...  Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase...
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase ... 11beta-hydroxysteroid dehydrogenase type 1 is an NADPH-dependent enzyme highly expressed in key metabolic tissues including ... Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase ... Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase ...
more infohttps://www.marketresearch.com/Global-Markets-Direct-v3480/Corticosteroid-Beta-Dehydrogenase-Isozyme-Hydroxysteroid-11955495/
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase...  Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase...
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase ... 11beta-hydroxysteroid dehydrogenase type 1 is an NADPH-dependent enzyme highly expressed in key metabolic tissues including ... Alpha Synuclein - Pipeline Review, H2 2019 Summary Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of ... Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase ...
more infohttps://www.reportbuyer.com/product/5380963/corticosteroid-11-beta-dehydrogenase-isozyme-1-11-beta-hydroxysteroid-dehydrogenase-1-or-short-chain-dehydrogenase-reductase-family-26c-member-1-or-hsd11b1-or-ec-1-1-1-146-pipeline-review-h1-2018.html
Postmenopausal asthma: the estradiol 11beta-hydroxysteroid dehydrogenase connection.  - PubMed - NCBI  Postmenopausal asthma: the estradiol 11beta-hydroxysteroid dehydrogenase connection. - PubMed - NCBI
Postmenopausal asthma: the estradiol 11beta-hydroxysteroid dehydrogenase connection.. Cohen PG, Holbrook JM. ...
more infohttps://www.ncbi.nlm.nih.gov/pubmed/15596647?dopt=Abstract
Research programme: 11-beta hydroxysteroid dehydrogenase type 1 inhibitors - Poxel - AdisInsight  Research programme: 11-beta hydroxysteroid dehydrogenase type 1 inhibitors - Poxel - AdisInsight
... is developing 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors for the ... Mechanism of Action 11-beta hydroxysteroid dehydrogenase type 1 inhibitors * Orphan Drug Status Orphan designation is assigned ... Research programme: 11-beta hydroxysteroid dehydrogenase type 1 inhibitors - Poxel Alternative Names: 11 beta HSD1 inhibitor - ... 21 Oct 2016 11-beta hydroxysteroid dehydrogenase type 1 inhibitors are still in Early research phase for Type-2 diabetes ...
more infohttps://adisinsight.springer.com/drugs/800032548?error=cookies_not_supported&code=480e00d9-928e-41cc-abbe-2c66721cc61d
11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.  - PubMed - NCBI  11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target. - PubMed - NCBI
At a tissue specific level, the enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) locally regenerates active ... 11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.. Tomlinson JW1. ... Here we review the role of 11beta-HSD1 in human disease and discuss the impact of selective 11beta-HSD1 inhibition. ... Furthermore, selective 11beta-HSD1 inhibition has been proposed as a novel therapeutic strategy in many of these conditions. ...
more infohttps://www.ncbi.nlm.nih.gov/pubmed/?term=15877012
11-Beta-Hydroxysteroid Dehydrogenase Type 1 (Hsd11b1) Antibody -Abbexa  11-Beta-Hydroxysteroid Dehydrogenase Type 1 (Hsd11b1) Antibody -Abbexa
11-Beta-Hydroxysteroid Dehydrogenase Type 1 (Hsd11b1) Antibody 由Abbexa供应,该产品简介:11-Beta-Hydroxysteroid Dehydrogenase Type 1 ( ... 产品名称:11-Beta-Hydroxysteroid Dehydrogenase Type 1 (Hsd11b1) Antibody ...
more infohttp://abbexa.bioleaf.com/Product_2061238823.html
Human 11-Beta-Hydroxysteroid Dehydrogenase Type 3 (HSD11b3) ELISA Kit - ELISA Kits - Products  Human 11-Beta-Hydroxysteroid Dehydrogenase Type 3 (HSD11b3) ELISA Kit - ELISA Kits - Products
Human 11-Beta-Hydroxysteroid Dehydrogenase Type 3 (HSD11b3) ELISA Kit 96 Tests $809.00 add to cart ... Human 11-Beta-Hydroxysteroid Dehydrogenase Type 3 (HSD11b3) ELISA Kit 96 Tests $809.00 add to cart ... This assay has high sensitivity and excellent specificity for detection of 11-Beta-Hydroxysteroid Dehydrogenase Type 3 ... No significant cross-reactivity or interference between 11-Beta-Hydroxysteroid Dehydrogenase Type 3 and analogues was observed ...
more infohttps://www.biomatik.com/products/elisa-kits/human-11-beta-hydroxysteroid-dehydrogenase-type-3-hsd11b3-elisa-kit.html
Hsd11b2 MGI Mouse Gene Detail - MGI:104720 - hydroxysteroid 11-beta dehydrogenase 2  Hsd11b2 MGI Mouse Gene Detail - MGI:104720 - hydroxysteroid 11-beta dehydrogenase 2
J:29215 Cole TJ, Cloning of the mouse 11 beta-hydroxysteroid dehydrogenase type 2 gene: tissue specific expression and ...
more infohttp://www.informatics.jax.org/marker/MGI:104720
Hydroxysteroid Dehydrogenase, 11-beta Type II peptide  Hydroxysteroid Dehydrogenase, 11-beta Type II peptide
Buy Hydroxysteroid Dehydrogenase, 11-beta Type II peptide (MBS653968) product datasheet at MyBioSource, Peptides. Application: ... Hydroxysteroid Dehydrogenase, 11-beta Type II, Peptide. ★Popular Item★ Also Known As Hydroxysteroid Dehydrogenase, 11-beta Type ... Hydroxysteroid Dehydrogenase, 11-beta Type II. LOG IN MY ACCOUNT CART CONTENTS CHECKOUT ... Small volumes of Hydroxysteroid Dehydrogenase, 11-beta Type II peptide vial(s) may occasionally become entrapped in the seal of ...
more infohttps://www.mybiosource.com/prods/Peptide/Hydroxysteroid-Dehydrogenase-11-beta-Type-II/datasheet.php?products_id=653968
11 beta hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess | 11β-Hydroxysteroid dehydrogenase...  11 beta hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess | 11β-Hydroxysteroid dehydrogenase...
Their findings showed that the D-bifunctional protein plays an essential role in the peroxisomal beta-oxidation pathway that ... Biochemical analysis showed that the 3-hydroxyacyl-CoA dehydrogenase activity of the D-bifunctional protein was completely ... 11 beta hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Media:. ... 11 beta hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. In 2 unrelated patients, Ulick et ...
more infohttp://oiu.steroids-australia.net/11-beta-hydroxysteroid-dehydrogenase-and-the-syndrome-of-apparent-mineralocorticoid-excess.html
Hsd17b11 MGI Mouse Gene Detail - MGI:2149821 - hydroxysteroid (17-beta) dehydrogenase 11  Hsd17b11 MGI Mouse Gene Detail - MGI:2149821 - hydroxysteroid (17-beta) dehydrogenase 11
View mouse Hsd17b11 Chr5:103989765-104021796 with: phenotypes, sequences, polymorphisms, proteins, references, function, expression
more infohttp://www.informatics.jax.org/marker/MGI:2149821
5 alpha-reductase and 11 beta-hydroxysteroid dehydrogenase activity in prepubertal Hispanic girls with premature adrenarche. -...  5 alpha-reductase and 11 beta-hydroxysteroid dehydrogenase activity in prepubertal Hispanic girls with premature adrenarche. -...
We studied C19 and C21 urinary steroid metabolites, 5 alpha/5 beta and 11 oxo/11 hydroxy metabolite pairs as well as the ratios ... of the total 5 alpha/total 5 beta and total 11 oxo/total 11 hydroxy metabolites in 24-h urine samples from 17 prepubertal ... We found no differences in the 5 alpha-reductase or 11 beta-hydroxysteroid dehydrogenase activities in the prepubertal girls ... Therefore, in this group of young girls, alterations in 5 alpha-reductase or 11 beta-hydroxysteroid dehydrogenase activities do ...
more infohttps://www.semanticscholar.org/paper/5-alpha-reductase-and-11-beta-hydroxysteroid-dehyd-Silfen-Shackleton/018ab3c0f96b12a4e7dcaa84e3ff157db6899159
KEE316Hu | ELISA kit for Homo sapiens (Human) 11-Beta-Hydroxysteroid Dehydrogenase Type 3 (HSD11b3) | Homo sapiens (Human) |...  KEE316Hu | ELISA kit for Homo sapiens (Human) 11-Beta-Hydroxysteroid Dehydrogenase Type 3 (HSD11b3) | Homo sapiens (Human) |...
Short chain dehydrogenase/reductase family 26C member 2 , Products for research use only! ... Short chain dehydrogenase/reductase family 26C member 2. * 96T (KEE316Hu) US$ 770 ... Elisa Kits › ELISA kit for Homo sapiens (Human) 11-Beta-Hydroxysteroid Dehydrogenase Type 3 (HSD11b3) ELISA kit for Homo ... The concentration of 11-Beta-Hydroxysteroid Dehydrogenase Type 3 (HSD11b3) in the samples is then determined by comparing the O ...
more infohttp://sinoprot.com/products/KEE316Hu
Tissue-specific dysregulation of 11 beta-hydroxysteroid dehydrogenase type 1 and pathogenesis of the metabolic syndrome |...  Tissue-specific dysregulation of 11 beta-hydroxysteroid dehydrogenase type 1 and pathogenesis of the metabolic syndrome |...
Elevenbeta-hydroxysteroid dehydrogenase type 1 (11beta-HSD-1), a key intracellular enzyme which catalyses the conversion of ... If confirmed, these results would prompt the development of selective and tissue-specific 11beta-HSD-1 inhibitors to decrease ... 11β-hydroxysteroid dehydrogenase type 1; Cortisol; Cortisone; Metabolic syndrome. Settore Scientifico Disciplinare: Settore MED ... studies are less convincing with several case control and cross-sectional studies showing an association between with 11beta- ...
more infohttps://air.unimi.it/handle/2434/200905
11beta-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle.  11beta-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle.
Within skeletal muscle, 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) converts cortisone (11-dehydrocorticosterone ... 11beta-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle.. ... 11beta-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle. 2009, 58 (11 ... 11beta-Hydroxysteroid dehydrogenase type 1 regulates insulin and glucagon secretion in pancreatic islets. ...
more infohttps://www.lenus.ie/handle/10147/254113
  • As a result, a number of pan-HDAC inhibitors have been examined for their ability to promote 11 β -HSD2 expression. (hindawi.com)
  • Here, we examined the ability of pan- and class-specific HDAC inhibitors to regulate 11 β -HSD2 expression in JEG3 cells. (hindawi.com)
  • If confirmed, these results would prompt the development of selective and tissue-specific 11beta-HSD-1 inhibitors to decrease insulin resistance and treat the metabolic syndrome, thus contrasting the harmful effects of glucocorticoid excess in peripheral tissues. (unimi.it)
  • We aimed to determine the mechanisms underpinning glucocorticoid-induced insulin resistance in skeletal muscle and indentify how 11beta-HSD1 inhibitors improve insulin sensitivity. (lenus.ie)
  • Importantly, 11beta-HSD1 activity appears to be intrinsically linked to all features of the metabolic syndrome, which could at least in animal experiments be modulated by use of synthetic selective inhibitors. (ox.ac.uk)
  • The recent development of specific 11beta-HSD1 inhibitors coupled with advances on structural knowledge and regulation of the 11beta-HSD1 target has undoubtedly promoted the understanding of glucocorticoid control of metabolic regulation. (ox.ac.uk)
  • Taken together, it appears that inhibitors against 11beta-HSD1 constitute a promising avenue for novel treatment strategies against the underlying causes of cardiovascular and other metabolic diseases. (ox.ac.uk)
  • 2006) Adamantane 11-beta-HSD-1 inhibitors: Application of an isocyanide multicomponent reaction. (guidetopharmacology.org)
  • Inhibition of the mitogen-activated protein kinases (MAPK) ERK1/2 increases HSD11B2 expression [ 12 ], whilst suppressing p38 reduces 11 β -HSD2 activity [ 13 ]. (hindawi.com)
  • Furthermore, selective 11beta-HSD1 inhibition has been proposed as a novel therapeutic strategy in many of these conditions. (nih.gov)
  • Here we review the role of 11beta-HSD1 in human disease and discuss the impact of selective 11beta-HSD1 inhibition. (nih.gov)
  • Inhibition of tissue-specific glucocorticoid activation by 11beta-HSD1 constitutes a promising target in the treatment of metabolic and cardiovascular diseases. (ox.ac.uk)
  • RESEARCH DESIGN AND METHODS: Rodent and human cell cultures, whole-tissue explants, and animal models were used to determine the impact of glucocorticoids and selective 11beta-HSD1 inhibition upon insulin signaling and action. (ox.ac.uk)
  • The benzothiazole derivatives 1 and 2 showed greater than 80% inhibition for 11beta-HSD1 at 10 microM and exhibited IC50 values in the low micromolar range. (ox.ac.uk)
  • Because of its inhibition of 11β-HSD and consequent potentiation of corticosteroids, 11α-OHP has recently been patented for the treatment of skin diseases, particularly psoriasis in combination with clobetasol propionate and minoxidil. (wikipedia.org)
  • In intact cells 11α-hydroxyprogesterone is a more potent inhibitor of 11β-HSD1 than glycyrrhetinic acid or 11β-hydroxyprogesterone (117, 118). (wikipedia.org)
  • Licorice, which contains glycyrrhetinic acid, or enoxolone, can inhibit 11β-HSD and lead to a mineralocorticoid excess syndrome. (wikipedia.org)
  • We studied C19 and C21 urinary steroid metabolites, 5 alpha/5 beta and 11 oxo/11 hydroxy metabolite pairs as well as the ratios of the total 5 alpha/total 5 beta and total 11 oxo/total 11 hydroxy metabolites in 24-h urine samples from 17 prepubertal Hispanic girls with premature adrenarche and seven controls. (semanticscholar.org)
  • Human dehydrogenase/reductase (SDR family) member 8 (DHRS8): a description and evaluation of its biochemical properties. (nih.gov)
  • 11beta-HSD1 activity and expression were observed in human and rodent myotubes and muscle explants. (ox.ac.uk)
  • Using monodispersity as a screening criterion, we have also optimized the purification process by evaluating various solubilizing systems for the chromatographic steps, finally obtaining stable monodisperse preparations of both human and guinea pig 11beta-HSD1. (ox.ac.uk)
  • Here, we report the discovery and synthesis of a series of novel benzothiazole derivatives and their inhibitory activities against 11beta-HSD1 from human hepatic microsomes measured using a radioimmunoassay (RIA) method. (ox.ac.uk)
  • Placental 11 β -HSD2 is known to be reduced in a number of adverse pregnancy complications, possibly through an epigenetic mechanism. (hindawi.com)
  • 11β-HSD1 is inhibited by carbenoxolone, a drug typically used in the treatment of peptic ulcers. (wikipedia.org)
  • 11 alpha-Hydroxyprogesterone (11 alpha OH-P) was an order of magnitude more potent a competitive inhibitor of the 11 beta HSD-2 than was glycyrrhetinic acid (GA) (approximate IC50 = 0.9 vs. 15 nM). (wikipedia.org)
  • Biochemical analysis showed that the 3-hydroxyacyl-CoA dehydrogenase activity of the D-bifunctional protein was completely inactive, whereas the enoyl-CoA hydratase component was active. (steroids-australia.net)
  • Their findings showed that the D-bifunctional protein plays an essential role in the peroxisomal beta-oxidation pathway that cannot be compensated for by the L-specific bifunctional protein. (steroids-australia.net)
  • Heterologous production of 11beta-HSD1, devoid of its N-terminal transmembrane segment, is possible but yields only small amounts of soluble protein. (ox.ac.uk)
  • By co-overexpressing GroEL/ES and adding an 11beta-HSD1 inhibitor during protein synthesis, we have increased the accumulation of soluble 11beta-HSD1 by more than one order of magnitude. (ox.ac.uk)
  • Increased 11beta-HSD1 activity and expression have been implicated in the pathogenesis of many common conditions including, obesity, insulin resistance, the metabolic syndrome, polycystic ovarian syndrome, osteoporosis and glaucoma. (nih.gov)
  • The compound has been found to be highly active in conferring mineralocorticoid sodium-retaining activity of corticosterone in vivo in rat bioassays and in increasing blood pressure, effects that it mediates by preventing the 11β-HSD-mediated inactivation of endogenous corticosteroids. (wikipedia.org)
  • 11β-HSD also reversibly catalyzes the conversion of 7-ketocholesterol to 7-beta-hydroxycholesterol. (wikipedia.org)
  • Formebolone (INN, BAN) (brand names Esiclene, Hubernol, Metanor), also known (confusingly) as formyldienolone, as well as 2-formyl-11α-hydroxy-17α-methyl-δ1-testosterone, is an orally active anabolic-androgenic steroid (AAS) described as an anticatabolic and anabolic drug that is or has been marketed in Spain and Italy. (wikipedia.org)
  • 11α Hydroxyprogesterone, while devoid of androgenic, estrogenic and progestational activity, is weakly anti androgenic in castrate rats. (wikipedia.org)
  • 11α-Hydroxyprogesterone is an important pharmaceutical compound with anti-androgenic and blood-pressure-regulating activity. (wikipedia.org)
  • 11α-Hydroxyprogesterone can therefore influence blood pressure regulation.12 Furthermore, 11α-hydroxyprogesterone exhibits an anti-androgenic activity with minimal estrogenic and progestational side effects.13 This substance was also recently patented for its role in treating skin diseases, especially for psoriasis in combination with clobetasol propionate and minoxidil.14. (wikipedia.org)
  • 11α-Hydroxyprogesterone (11α-OHP), or 11α-hydroxypregn-4-ene-3,20-dione is an endogenous steroid and metabolite of progesterone. (wikipedia.org)
  • Roxibolone (INN) (developmental code name BR-906), also known as 11β,17β-dihydroxy-17α-methyl-3-oxoandrosta-1,4-diene-2-carboxylic acid, is a steroidal antiglucocorticoid described as an anticholesterolemic (cholesterol-lowering) and anabolic drug which was never marketed. (wikipedia.org)
  • As roxibolone is 11β-hydroxylated similarly, it may act in a likewise fashion. (wikipedia.org)